Last reviewed · How we verify
Paclitaxel, Carboplatin
Paclitaxel and carboplatin work together as a chemotherapy combination that stabilizes microtubules and causes DNA damage to kill cancer cells.
Paclitaxel and carboplatin work together as a chemotherapy combination that stabilizes microtubules and causes DNA damage to kill cancer cells. Used for Gynecological cancers (ovarian, endometrial, cervical cancer), First-line and recurrent ovarian cancer.
At a glance
| Generic name | Paclitaxel, Carboplatin |
|---|---|
| Sponsor | Queensland Centre for Gynaecological Cancer |
| Drug class | Chemotherapy combination (taxane + platinum agent) |
| Target | Microtubules (paclitaxel); DNA (carboplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Paclitaxel is a taxane that binds to microtubules and prevents their disassembly, disrupting cell division. Carboplatin is a platinum-based agent that forms DNA crosslinks, causing irreparable DNA damage. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Gynecological cancers (ovarian, endometrial, cervical cancer)
- First-line and recurrent ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Nausea and vomiting
- Alopecia
- Fatigue
- Hypersensitivity reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1) (NA)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel, Carboplatin CI brief — competitive landscape report
- Paclitaxel, Carboplatin updates RSS · CI watch RSS
- Queensland Centre for Gynaecological Cancer portfolio CI